Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interferenc...
| Main Authors: | , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2016
|
| Online Access: | http://hdl.handle.net/1721.1/105539 https://orcid.org/0000-0002-0013-3941 https://orcid.org/0000-0002-1090-6071 |